Coverage / LON:AVCT / Trade Card

LON:AVCT

Avacta Group Plc

OPPORTUNISTIC BUY Analysis generated 2026-10-28 Market data as of 2026-11-13 Market data 2 days old 58.02p Healthcare - Biotechnology
ACTIONABLEMethodology gates passed
59

Position levels

Currenttoday
58.02p
Buy <=wait / entry
-
Trim >=take some off
-
Thesis breaknot set
-

Scenario-weighted conviction

ProbabilityScoreContribution
Bull case25%100 / 10025.0
Base case50%62 / 10031.0
Bear case25%10 / 1002.5
Weighted conviction59 / 100 - OPPORTUNISTIC BUY

Top risks

  • FDA agreement on pivotal trial design for AVA6000 in salivary gland cancer (June 2026)
  • Notice of interim results investor meeting scheduled for 15 Oct 2026 with CEO and CFO presentation
  • AVA6000 lead candidate continues in Phase 1b with data presentation anticipated in October 2026
Read full report →

Research is for informational purposes only. Not financial advice. All analysis reflects the date of publication.

\n